| Glaucoma Medication Groups | Medicine | Formulation and strength | Availability n (%) | Target Size Pack |
| Alpha-Adrenergic Receptor Agonists | Apraclonidine | Eye drop, 0.5% | 0 (0.0%) | 5 mL |
| Brimonidine | Eye drop, 0.2% | 4 (10.3%) | 5 mL | |
| Beta-Blockers | Timolol | Eye drop, 0.5% | 28 (71.8%) | 5 mL |
| Carteolol | Eye drop, 1% | 0 (0.0%) | 5 mL | |
| Levobunolol | Eye drop, 0.5% | 0 (0.0%) | 5 mL | |
| Betaxolol | Eye drop, 0.5% | 3 (7.7%) | 5 mL | |
| Cholinergic Agonists | Pilocarpine | Eye drop, 1% | 2 (5.1%) | 10 mL |
| Carbachol | Eye drop, 3% | 0 (0.0%) | 15 mL | |
| Carbonic Anhydrase Inhibitors | Acetazolamide | Tablet, 250 mg | 7 (17.9%) | 30 Tablets |
| Brinzolamide | Eye drop, 1% | 0 (0.0%) | 5 mL | |
| Dorzolamide | Eye drop, 2% | 5 (12.8%) | 5 mL | |
| Prostaglandin Analogues | Bimatoprost | Eye drop, 0.03% | 0 (0.0%) | 3 mL |
| Travoprost | Eye drop, 0.004% | 0 (0.0%) | 2.5 mL | |
| Unoprostone | Eye drop, 0.15% | 0 (0.0%) | 5 mL | |
| Latanoprost | Eye drop, 0.005% | 3 (7.7%) | 2.5 mL | |
| Mean availability of glaucoma medicines in percentage | 8.89 | |||
| Availability category Level n (%) | Very low | Low | Fairly high | High |
| <30% | 30 - <50% | 50 - <80% | ≥80% | |
| 14 (93.3) | 0 (0.0) | 1 (6.67) | 0 (0.0) | |